β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancer | Zendy

Annika Eurola | Zendy; Ari Ristimäki | Zendy; Harri Mustonen | Zendy; Anurmi | Zendy; Jaana Hagström | Zendy; Pauliina Kallio | Zendy; Kari Alitalo | Zendy; Caj Haglund | Zendy; Hanna Seppänen | Zendy

Open Access

β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancer

Author(s) -

Annika Eurola,

Ari Ristimäki,

Harri Mustonen,

Anurmi,

Jaana Hagström,

Pauliina Kallio,

Kari Alitalo,

Caj Haglund,

Hanna Seppänen

Publication year - 2022

Publication title -

tumor biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.055

H-Index - 84

eISSN - 1423-0380

pISSN - 1010-4283

DOI - 10.3233/tub-211581

Subject(s) - immunostaining , medicine , pancreatic cancer , oncology , catenin , cancer , tumor progression , immunohistochemistry , disease , cancer research , gastroenterology , biology , wnt signaling pathway , gene , biochemistry

Wnt/β-catenin signaling is a highly conserved signaling pathway that regulates the transcription factor PROX1. The role of β-catenin and PROX1 in pancreatic cancer is ambiguous, as some studies have associated their expression with tumor regression and some with tumor progression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research